Regado slashes staff to preserve cash following PhIII fiasco

John Carroll Regado had all of its eggs in one basket when it took its lead therapy into a Phase III trial on its own. And now that the anticoagulant study has been shelved after signs ...

Copay coupons get the Inspector General treatment

Tracy Staton The HHS Inspector General's office says the fine print isn't enough to safeguard against Medicare recipients' coupon use. Drugmakers have to do more–or ...

First-to-market launch? Bonus–but double bonus if you’re Big Pharma

Tracy Staton When it comes to launching a next-generation drug, first is always best, right? Press releases can call it a "first-in-class" product. Sales and marketing teams ...

Boehringer pairs its lung cancer drug with a vaccine in $600M tie-up with CureVac

John Carroll FierceBiotech News

Which body parts warrant the biggest biotech venture investments?

John Carroll Dow Jones writer Brian Gormley set out to find out the answer to that question, reviewing the venture data for biotech and med tech in Dow Jones' VentureSource database. FierceBiotech ...

Pfizer, Ranbaxy prevail in antitrust fight over Lipitor generics

Tracy Staton Pfizer and Ranbaxy Laboratories persuaded a U.S. judge to toss out an antitrust lawsuit accusing them of conspiring to delay generic versions of the cholesterol-fighting ...

Cyramza, key to Lilly’s oncology hopes, comes through in colorectal cancer

Damian Garde Eli Lilly's Cyramza (ramucirumab) met its primary endpoint in a study on metastatic colorectal cancer, good news for a key cog in the drugmaker's plans to capitalize ...

Lilly says with new data, it will seek another approval for Cyramza next year

Eric Palmer Eli Lilly has harbored big hopes for its newly approved cancer fighter Cyramza. It expects it to get a string approvals, and with new data in hand, it said it will go to ...

Could political pressure be stalling Hospira’s Danone inversion deal?

Carly Helfand Many a U.S. drugmaker has pounced on an opportunity to pick up a foreign company, haul overseas and reap the tax rewards. But while rumors this summer said Illinois-based ...

AZ strikes Alderley cancer pact, Cerenis mulls IPO, 4D to start microbiome trials in 2015

Nick Paul Taylor Welcome to the latest edition of our weekly EuroBiotech Report. FierceBiotech News

AbbVie partners with Google’s Calico on $1.5B R&D operation focused on aging

John Carroll Hot on the heels of its $ 805 million development deal with Infinity, AbbVie Pharmaceuticals has followed up today with a plan to partner with Google's closely watched ...

It’s megablockbuster halfsies for Sanofi, Amgen in next new cholesterol market

Tracy Staton When is cholesterol fighting a game of six of one, half dozen of the other? Could be when the contest is between Amgen and its PCSK9 inhibitor evolocumab, and Sanofi and ...
Page 1 of 212
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS